Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...

PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

The Microbiomes Market is experiencing significant growth due to the increasing research and development in the field of ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?